TRT and hair loss: what the evidence actually says

What did @modernwellnessclinic actually say?

The creator made three core claims: TRT won't reverse balding, high doses of testosterone accelerate hair loss, and using TRT at "safe doses" won't affect your hairline. They also recommended finasteride (called "propecia" in the transcript) along with minoxidil-based drops and medicated shampoo as a protective hair-care regimen.

The pitch ends with a plug for their telehealth clinic, which is worth flagging upfront. This is a promotional video, not a neutral explainer. The creator uses their own hair as anecdotal evidence, saying "look at my hair, everything is good, it's not falling off." That's not science. That's one person's head.

Still, the underlying pharmacology they're gesturing at is real, even if the framing is sloppy. Let's work through it.

Does the science back this up?

Partially, yes. The relationship between testosterone and hair loss is real but more complicated than "high dose bad, low dose fine." The actual driver of androgenic alopecia is dihydrotestosterone (DHT), a metabolite of testosterone converted by the enzyme 5-alpha reductase, not testosterone itself.

When you add exogenous testosterone through TRT, you raise the substrate available for DHT conversion. Whether that accelerates hair loss depends heavily on individual genetics, specifically androgen receptor sensitivity in hair follicles. Men with a strong genetic predisposition to androgenic alopecia can see acceleration even at physiologic testosterone levels.

A 2020 review by Randolph and Bhatt in the Journal of the American Academy of Dermatology confirmed that androgens are a primary driver of pattern hair loss, but noted that the degree of follicular sensitivity varies widely between individuals. The idea that "safe doses" of TRT universally protect hair is not supported. For genetically susceptible men, any increase in circulating testosterone can worsen loss.

Finasteride does have solid evidence behind it. A landmark trial by Kaufman et al. (1998, Journal of the American Academy of Dermatology) showed that 1mg daily finasteride significantly slowed hair loss and promoted regrowth in men with androgenic alopecia by blocking 5-alpha reductase and lowering DHT.

What did they get wrong (or right)?

They got the finasteride and minoxidil recommendations directionally right. Both are FDA-approved for male pattern hair loss, and combining TRT with a DHT blocker like finasteride is a clinically reasonable harm-reduction approach. That part isn't wrong.

What they got wrong is the implied guarantee in "safe doses" of TRT protecting your hair. There is no universally safe dose of testosterone for hair preservation. Hair follicle androgen sensitivity is genetic, and some men will lose hair on physiologic testosterone replacement, full stop. Presenting this as avoidable through dose management alone is misleading to an audience that may not understand DHT biology.

The creator also conflates "Propecia" and "finasteride" as if they're separate options, saying "we prescribe propecia or finasteride." Propecia is a brand name for finasteride. This is either a scripting error or a sign the creator isn't as clinically precise as they're presenting themselves to be.

Using personal hair as evidence of TRT safety is not a clinical argument. It's anecdote, and it doesn't account for the variation in genetic susceptibility across their patient population.

What should you actually know?

If you're on TRT or considering it, here's what the evidence actually supports. DHT, not testosterone directly, is the main culprit in androgenic alopecia. Your genetic sensitivity to DHT at the follicle level matters far more than your total testosterone dose.

Finasteride reduces scalp DHT by roughly 60 to 70 percent (Kaufman et al., 1998) and is the most evidence-backed pharmacological option for men on TRT who want to protect their hair. Minoxidil ("minoxidil drops" or "oxydil" as mentioned in the transcript) is a vasodilator that promotes hair growth through a separate mechanism and has a solid evidence base as an adjunct treatment.

However, finasteride carries its own risk profile. Post-finasteride syndrome, including persistent sexual dysfunction, depression, and cognitive effects in a subset of men, is a real reported phenomenon documented in patient case series, though causality remains debated. A provider recommending finasteride without discussing this is not giving complete informed consent.

• Ask your provider about your genetic risk for androgenic alopecia before starting TRT.
• DHT levels, not just total testosterone, are worth monitoring if hair loss is a concern.
• Finasteride is FDA-approved and evidence-backed, but discuss side effect risks before starting.
• No dose of TRT is guaranteed to be hair-neutral for genetically susceptible men.
• Telehealth platforms should be disclosing their prescribing protocols, not using TikTok hair selfies as clinical evidence.